Search Results for: PERSONALIZED MEDICINE Targeted Personalized Therap
Articles
BIND Therapeutics & AstraZeneca Announce Lucrative Worldwide Agreement April 28, 2013
BIND Therapeutics and AstraZeneca recently announced it has entered into a strategic collaboration to develop and commercialize an Accurin, a...Mission Bio's New Translocation Analysis Offers Insights Into Critical Safety Assessment for Gene-Edited Cell Products April 25, 2024
Mission Bio recently announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited...SPECIAL FEATURE - Excipients: Advanced Biologics Require Innovative Excipient Science March 29, 2024
Contributor Cindy H. Dubin speaks with several leading companies to discuss novel and functional excipients being developed, the role they will play in reformulations and new formulations, and their versatility in drug delivery.
CANCER BIOMARKERS - Co-Analysis of CTCs & ctDNA: Gaining Multi-Dimensional Insights Into Cancer Heterogeneity March 28, 2024
Yoon-Tae Kang, PhD, Abiodun Bodunrin, PhD, and Joby Chesnick, PhD, MBA, believe co-analysis of CTC abundance and phenotypic changes together with ctDNA concentration could allow for real-time monitoring of disease progression and reoccurrence, while genetic and epigenetic changes in CTCs and ctDNA mutations over time could provide valuable insights into the effectiveness of therapeutic interventions, as the presence of different somatic mutations may indicate cancer susceptibility or resistance to certain treatments.
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Putting Customers First June 5, 2023
Contributor Cindy H. Dubin speaks with several leading CDMOs from around the globe on their unique development and manufacturing capabilities and technologies, and presents real-world examples of how they have put these to use to produce innovative compounds, lower development costs, and shorten time to market.
Mekonos Announces Research Collaboration With bit.bio to Advance Cell Engineering May 10, 2023
New collaboration combines Mekonos’ novel ex vivo delivery platform with bit.bio’s unique opti-ox™ precision cellular reprogramming technology to accelerate the development of human cells for research, drug discovery and….
Absci Partners With Bioinformatics Company M2GEN to Accelerate Drug Creation for Oncology April 4, 2023
Absci Corporation and M2GEN recently announced a partnership to create new cancer medicines and bring them to market at unprecedented speed. Absci’s generative AI drug creation platform will tap into M2GEN’s clinical and….
EXECUTIVE INTERVIEW - PCI Pharma Services: The Global, Integrated CDMO Partner of Choice April 3, 2023
John Ross, Senior Vice President of Development and Manufacturing at PCI Pharma Services, discusses what it means to be the partner of choice in a very dynamic industry.
Exelixis & Catalent Enter New License Agreement for Three Antibody-Drug Conjugate Programs With the Potential to Accelerate Exelixis’ Biologics Pipeline November 3, 2022
Exelixis, Inc. and Catalent, Inc. recently announced a new license agreement under which Catalent’s Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs with….
PLATFORM TECHNOLOGY - The Evolution of Cancer Vaccines: Moving Beyond Failure & a New Era for Cancer Treatment October 3, 2022
Jeremy R. Graff, PhD, says new studies show promising data with the use of mRNA-based vaccines and the injection of nanoparticles into regional lymph nodes to achieve disease stabilization. This has led to a potentially groundbreaking era of therapeutic cancer vaccines thanks to discoveries in identifying truncal targets, targeting tumor neoantigens and, notably, developing improved delivery technologies that stimulate a robust, targeted, and persistent immune response.
SPECIAL FEATURE - Injection Devices: Three Trends Influencing Development & Delivery September 1, 2022
Contributor Cindy H. Dubin showcases in this annual feature how various innovative device manufacturers are addressing the current trends in their injection designs.
Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD With AIM Biologicals Program June 14, 2022
Aeterna Zentaris Inc. recently announced its Autoimmunity Modifying (AIM) Biologicals program has achieved preclinical proof-of-concept for the potential treatment of...SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product June 1, 2022
Contributor Cindy H. Dubin speaks with industry leaders on how drug sponsors and CDMOs are collaborating earlier, and highlights how third-party contractors are navigating material shortages and how the industry is shifting to address different therapeutic targets and molecules, such as mRNA.
Adial Pharmaceuticals Announces Research Collaboration With UC San Diego May 4, 2022
Adial Pharmaceuticals, Inc. recently announced Purnovate, Inc., an Adial company focused on developing adenosine analogs for the treatment of major….
EXECUTIVE INTERVIEW - PCI Pharma Services: Broadening Our Biologics Footprint, Together May 2, 2022
Shawn Cain, SVP Development & Manufacturing at PCI Pharma Services, discusses the recent acquisition, the opportunities this presents to Biopharma companies, and the current trends in the sterile fill-finish industry.
Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined With Capecitabine (Next-Generation Capecitabine) April 20, 2022
Processa Pharmaceuticals, Inc. recently announced the first patient with advanced, refractory gastrointestinal cancer has been dosed in its amended maximum...Catalent & TFF Pharmaceuticals Announce New Inhalation Dry Powder Development & Manufacturing Agreement March 1, 2022
Catalent and TFF Pharmaceuticals, Inc. recently announced their collaboration agreement focused on the generation, testing, and manufacture of dry powder...Processa Pharmaceuticals Announces Next- Generation Capecitabine Inhibits DPD in Phase 1b Interim Analysis November 4, 2021
Processa Pharmaceuticals, Inc. recently announced the company’s Next-Generation Capecitabine dosage regimen (a combination of PCS6422 administered with capecitabine) successfully inhibited...Interpace Diagnostics Announces US Patent Approval: MicroRNAs as Biomarkers for Distinguishing Benign From Malignant Thyroid Neoplasms October 21, 2021
Interpace Biosciences, Inc. recently announced the United States Patent and Trademark Office granted it a Patent (US PTO Number 11,118,231...Nuvectis Pharma Raises $15 Million & In-Licenses Exclusive Worldwide Rights to Novel Selective HSF1 Pathway Inhibitor From the CRT Pioneer Fund August 31, 2021
Nuvectis Pharma, Inc. recently announced the completion of a $15-million Series A Preferred Stock financing with institutional and private investors....
